- Home
- NRXS vs CLRB Comparison
NRXS vs CLRB Comparison
Compare NRXS & CLRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRXS
- CLRB
- Stock Information
- Founded
- NRXS 2011
- CLRB 2002
- Country
- NRXS United States
- CLRB United States
- Employees
- NRXS N/A
- CLRB N/A
- Industry
- NRXS
- CLRB Biotechnology: Pharmaceutical Preparations
- Sector
- NRXS
- CLRB Health Care
- Exchange
- NRXS Nasdaq
- CLRB Nasdaq
- Market Cap
- NRXS 12.5M
- CLRB 12.6M
- IPO Year
- NRXS 2023
- CLRB N/A
- Fundamental
- Price
- NRXS $2.34
- CLRB $0.31
- Analyst Decision
- NRXS
- CLRB Hold
- Analyst Count
- NRXS 0
- CLRB 1
- Target Price
- NRXS N/A
- CLRB N/A
- AVG Volume (30 Days)
- NRXS 36.9K
- CLRB 619.5K
- Earning Date
- NRXS 05-21-2025
- CLRB 05-13-2025
- Dividend Yield
- NRXS N/A
- CLRB N/A
- EPS Growth
- NRXS N/A
- CLRB N/A
- EPS
- NRXS N/A
- CLRB N/A
- Revenue
- NRXS $2,685,925.00
- CLRB N/A
- Revenue This Year
- NRXS $138,883.78
- CLRB N/A
- Revenue Next Year
- NRXS $118.59
- CLRB N/A
- P/E Ratio
- NRXS N/A
- CLRB N/A
- Revenue Growth
- NRXS 9.18
- CLRB N/A
- 52 Week Low
- NRXS $1.33
- CLRB $0.22
- 52 Week High
- NRXS $3.78
- CLRB $3.51
- Technical
- Relative Strength Index (RSI)
- NRXS 65.87
- CLRB 53.10
- Support Level
- NRXS $1.33
- CLRB $0.23
- Resistance Level
- NRXS $2.09
- CLRB $0.32
- Average True Range (ATR)
- NRXS 0.36
- CLRB 0.03
- MACD
- NRXS 0.06
- CLRB 0.00
- Stochastic Oscillator
- NRXS 90.95
- CLRB 90.33
About NRXS Neuraxis Inc.
Neuraxis Inc is a growth stage company is engaged in developing neuromodulation therapies to address chronic and debilitating conditions in children. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).
About CLRB Cellectar Biosciences Inc.
Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage a proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. It has one operating and reportable segment focused on utilizing its PDC platform to develop drugs for the treatment of cancer.